Literature DB >> 17687100

Pathological networking: a new approach to understanding COPD.

Ian Sabroe1, Lisa C Parker, Peter M A Calverley, Steven K Dower, Moira K B Whyte.   

Abstract

Developing new treatments for chronic obstructive pulmonary disease (COPD) is extremely challenging. This disease, chronic by definition, becomes apparent only after substantial-and probably irreversible-tissue damage has occurred. The observable phenotype is of a stable disease state whose progression is hard to influence and reversal of which appears almost impossible. Identifying key components of the pathological process, targeting of which will result in substantial clinical benefit, is a significant challenge. In this review the nature of the disease is examined and conceptual information and simple tissue models of inflammation are used to explore the pathological network that is COPD. From the concept of COPD as a disease network displaying the features of contiguous immunity (in which many processes of innate and adaptive immunity are in continual dialogue and evolution), refinements are suggested to the strategies aimed at developing effective new treatments for this disease.

Entities:  

Mesh:

Year:  2007        PMID: 17687100      PMCID: PMC2117289          DOI: 10.1136/thx.2007.077768

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  70 in total

1.  Monocyte/macrophage-derived microparticles up-regulate inflammatory mediator synthesis by human airway epithelial cells.

Authors:  Chiara Cerri; Daniele Chimenti; Ilaria Conti; Tommaso Neri; Pierluigi Paggiaro; Alessandro Celi
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

Review 2.  Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity.

Authors:  A G Bowie
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  A three-dimensional in vitro model of angiogenesis in the airway mucosa.

Authors:  H Garrett Thompson; David T Truong; Craig K Griffith; Steven C George
Journal:  Pulm Pharmacol Ther       Date:  2006-01-18       Impact factor: 3.410

4.  Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.

Authors:  Klaus F Rabe; Tito Atienza; Pál Magyar; Per Larsson; Carin Jorup; Umesh G Lalloo
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

Review 5.  Is IL-1 a good therapeutic target in the treatment of arthritis?

Authors:  Danielle Burger; Jean-Michel Dayer; Gaby Palmer; Cem Gabay
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-10       Impact factor: 4.098

6.  Association between markers of emphysema and more severe chronic obstructive pulmonary disease.

Authors:  P Boschetto; S Quintavalle; E Zeni; S Leprotti; A Potena; L Ballerin; A Papi; G Palladini; M Luisetti; L Annovazzi; P Iadarola; E De Rosa; L M Fabbri; C E Mapp
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

7.  Roger s. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance.

Authors:  Bartolome R Celli
Journal:  Proc Am Thorac Soc       Date:  2006-08

Review 8.  Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease.

Authors:  Andrei E Medvedev; Ian Sabroe; Jeffrey D Hasday; Stefanie N Vogel
Journal:  J Endotoxin Res       Date:  2006

Review 9.  Identifying and hurdling obstacles to translational research.

Authors:  Ian Sabroe; David H Dockrell; Stefanie N Vogel; Stephen A Renshaw; Moira K B Whyte; Steven K Dower
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

10.  Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses.

Authors:  Gavin E Morris; Lisa C Parker; Jon R Ward; Elizabeth C Jones; Moira K B Whyte; Christopher E Brightling; Peter Bradding; Steven K Dower; Ian Sabroe
Journal:  FASEB J       Date:  2006-08-25       Impact factor: 5.191

View more
  7 in total

1.  Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.

Authors:  Antonello Punturieri; Eva Szabo; Thomas L Croxton; Steven D Shapiro; Steven M Dubinett
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

2.  Role of interleukin-1 and MyD88-dependent signaling in rhinovirus infection.

Authors:  Clare A Stokes; Saila Ismail; Emily P Dick; Julie A Bennett; Sebastian L Johnston; Michael R Edwards; Ian Sabroe; Lisa C Parker
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

3.  Tracing personalized health curves during infections.

Authors:  David S Schneider
Journal:  PLoS Biol       Date:  2011-09-20       Impact factor: 8.029

4.  Scale-free networks in metabolomics.

Authors:  Hema Sekhar Reddy Rajula; Matteo Mauri; Vassilios Fanos
Journal:  Bioinformation       Date:  2018-03-31

Review 5.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01

6.  A phosphatidylserine species inhibits a range of TLR- but not IL-1beta-induced inflammatory responses by disruption of membrane microdomains.

Authors:  Lisa C Parker; Elizabeth C Prestwich; Jon R Ward; Elizabeth Smythe; Anthony Berry; Martha Triantafilou; Kathy Triantafilou; Ian Sabroe
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

7.  Susceptibility to COPD: differential proteomic profiling after acute smoking.

Authors:  Lorenza Franciosi; Dirkje S Postma; Maarten van den Berge; Natalia Govorukhina; Peter L Horvatovich; Fabrizia Fusetti; Bert Poolman; Monique E Lodewijk; Wim Timens; Rainer Bischoff; Nick H T ten Hacken
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.